Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy - Seite 4
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500-5,000 males
worldwide. DMD is caused by a change or mutation in the gene that encodes instructions for dystrophin. Symptoms of DMD usually appear in infants and toddlers. Affected children may experience
developmental delays such as difficulty in walking, climbing stairs or standing from a sitting position. As the disease progresses, muscle weakness in the lower limbs spreads to the arms, neck and
other areas. Most patients require full-time use of a wheelchair in their early teens, and then progressively lose the ability to independently perform activities of daily living such as using the
restroom, bathing and feeding. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure.
The condition is universally fatal, and patients usually succumb to the disease in their twenties.
About Sarepta Therapeutics
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with
rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA,
Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic
modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or
follow us on Twitter, LinkedIn, Instagram and
Facebook.
Lesen Sie auch
Sarepta Forward-Looking Statement
This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements.
These forward-looking statements include statements regarding the potentially transformative benefits of SRP-9001; our plan to analyze the functional results for all the patients in Study 102 once
they have achieved the 48-week timepoint; the expectation to have biomarker and safety results from Study 103 in the second quarter of 2021; our plan to use the information and insight from Study
102 to refine and complete the protocol for our upcoming trial using commercial process material; and our intention to continue to move forward with diligence and urgency to generate the evidence
necessary to bring SRP-9001 to waiting Duchenne patients around the world.